SL Science Holding pops at Nasdaq open, SPAC risks linger
SLBT soared to $18.90 in early Tuesday trading after plunging 42.59% on its Nasdaq debut, as investors reacted to SL Bio’s SPAC merger and $7.8 million PIPE financing; with no new clinical data disclosed, trading was driven by liquidity and momentum, while major execution and funding risks remain.